NASDAQ: PLURPluri Inc Stock
$4.95-0.14 (-2.75%)
Updated Jun 30, 2025
PLUR Price
$4.95
Fair Value Price
N/A
Market Cap
$38.77M
52 Week Low
$3.33
52 Week High
$7.13
P/E
-1.37x
P/B
N/A
P/S
27.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.03M
Earnings
-$20.71M
Gross Margin
52.1%
Operating Margin
-2,082.79%
Profit Margin
-2,003.3%
Debt to Equity
N/A
Operating Cash Flow
-$17M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLUR Overview
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLUR's potential to beat the market
- PLUR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PLUR news, forecast changes, insider trades & much more!
PLUR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLUR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PLUR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PLUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PLUR due diligence checks available for Premium users.
Valuation
PLUR fair value
Fair Value of PLUR stock based on Discounted Cash Flow (DCF)
Price
$4.95
Fair Value
-$5.32
Undervalued by
193.01%
PLUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.37x
Industry
-123.86x
Market
32.47x
PLUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
4.44x
PLUR's financial health
Profit margin
Revenue
$427.0k
Net Income
-$6.1M
Profit Margin
-1,439.6%
PLUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLUR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$37.4M
Liabilities
$0.0
Debt to equity
0
Cash flow
Operating
-$4.3M
Investing
-$4.2M
Financing
$0.0
PLUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLUR vs Biotech Stocks
Pluri Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.